Table 3 Demographic and clinical characteristics of the Derivation, Validation and Easton cohorts.

From: Clinical Model for Predicting Warfarin Sensitivity

Variable

IWPC Cohort

Easton Cohort

(N = 106)

Derivation Cohort (N = 4433)

Validation Cohort (N = 1109)

P Value*

Warfarin dose—mg/week

  

0.36

 

  Median

28.0

28.0

 

27.5

  Interquartile range

20.0–40.1

21.0–41.3

 

17.5–37.9

Genotype—no. (%)

   VKORC1 rs9923231

  

0.34

 

      G/G

1473 (33.2)

372 (33.5)

 

35 (33.0)

      A/G

1651 (37.2)

389 (35.1)

 

54 (50.9)

      A/A

1309 (29.5)

348 (31.4)

 

17 (16.0)

   CYP2C9

  

0.12

 

      *1/*1

3330 (75.1)

856 (77.2)

 

62 (58.5)

      *1/*2

587 (13.2)

150 (13.5)

 

21 (19.8)

      *1/*3

403 (9.1)

75 (6.8)

 

19 (17.9)

      *2/*2

47 (1.1)

11 (1.0)

 

1 (0.1)

      *2/*3

51 (1.2)

16 (1.4)

 

3 (2.8)

      *3/*3

15 (0.3)

1 (0.1)

 

0 (0)

Age—no. (%)

  

0.65

 

    <50

738 (16.6)

192 (17.3)

 

2 (1.9)

    50–80

3146 (71.0)

790 (71.2)

 

56 (52.8)

    >80

549 (12.4)

127 (11.5)

 

48 (45.3)

Height—m

  

0.35

 

  Median

167.6

167.6

 

170.2

  Interquartile range

160.0–175.4

160.0–176.5

 

162.6–175.3

Weight—kg

  Median

75.9

76.0

0.76

80.5

  Interquartile range

63.0–90.7

63.0–91.0

 

69.9–94.3

Race—no. (%)

  

0.44

 

  White

2418 (54.5)

585 (52.8)

 

106 (100)

  Asian

1161 (26.2)

298 (26.9)

  

  Black

492 (11.1)

140 (12.6)

  

  Mixed or missing

362 (8.2)

86 (7.8)

  

Amiodarone

211 (4.8)

58 (5.2)

0.51

10 (9.4)

  1. *P values for the difference between the derivation and validation cohorts were calculated with the use of the Wilcoxon rank-sum test for warfarin dose, height, and weight, Fisher’s exact test for CYP2C9 genotype, χ2 tests were used for VKORC1 rs9923231 genotype, age, and race, and the z-test for proportions for the use of amiodarone.
Back to article page